Latest news with #TLT
Yahoo
13-06-2025
- Business
- Yahoo
Israel's Strikes on Iran Boost Safe Haven ETF Demand
The tensions in the Middle East escalated after Israel launched a wave of airstrikes on Iran, triggering a sharp sell-off across global markets. Iran is preparing to retaliate as it has launched around 100 drones toward Israel, raising fears of a broader regional conflict. Markets reacted swiftly to the news, with the three major gauges plunging more than 1% in pre-market trade today. Meanwhile, the U.S. dollar, Japanese yen and Swiss franc all strengthened, while crude prices spiked sharply amid fears of potential supply disruptions. Gold surged to its highest level since early May and U.S. Treasury price also rose. Investors are flocking to safe-haven bids, which offer protection in times of heightened such a backdrop, we have highlighted five safe-haven ETFs that investors should add to their portfolio, especially if Middle East tensions continue to escalate. These products will likely benefit from the crisis and will be in focus in the weeks - SPDR Gold Trust ETF (GLD)Gold, viewed as a safe haven, has been on a strong rally this year, reaching new all-time highs on several occasions, buoyed by trade gyrations. The yellow metal serves as a hedge against market turmoil and is often used as a means of preserving wealth during times of financial and political uncertainty, typically performing well when other asset classes struggle. As such, the ultra-popular product tracking this bullion, like GLD, could be an interesting pick. The fund tracks the price of gold bullion measured in U.S. dollars and kept in London under the custody of HSBC Bank and JPMorgan Chase Bank. GLD is an ultra-popular gold ETF with an AUM of $99.9 billion and a heavy volume of about 11 million shares a day. SPDR Gold Trust ETF charges 40 bps in fees per year from investors and has a Zacks ETF Rank #3 (Hold) with a Medium risk outlook (read: Gold Surges Amid Global Risks: ETFs to Buy).Long-Dated Treasury - iShares 20+ Year Treasury Bond ETF (TLT)Products tracking the long end of the yield curve often provide a safe haven. The 10-year Treasury yields dropped to a one-month low of 4.31%, pushing bonds higher. TLT tracks the ICE U.S. Treasury 20+ Year Bond Index and has an AUM of $48.6 billion. Holding 42 securities in its basket, the fund focuses on the top credit-rating bonds with an average maturity of 25.78 years and an effective duration of 15.70 years. The expense ratio comes in at 0.15%, and the average daily volume is heavy at around 43 million shares. However, TLT currently has a Zacks ETF Rank #4 (Sell).Dollar - Invesco DB US Dollar Index Bullish Fund (UUP)After hitting a 3-year low in yesterday's trading session, the U.S. dollar rose 0.6% (at the time of writing) against a basket of major currencies on news that Israel had launched strikes on Iran. Invesco DB US Dollar Index Bullish Fund is the prime beneficiary of the rising dollar as it offers exposure against a basket of six world currencies. This is done by tracking the Deutsche Bank Long USD Currency Portfolio Index - Excess Return plus the interest income from the fund's holdings of U.S. Treasury securities. In terms of holdings, Invesco DB US Dollar Index Bullish Fund allocates nearly 57.6% in euro and 25.5% collectively in the Japanese yen and British pound (read: ETFs on the Move Post U.S.-China Trade Deal). The fund managed an asset base of $200.2 million, with an average daily volume of around 948,000 shares. UUP charges 78 bps of annual fees and has a Zacks ETF Rank #3 with a Medium risk - Invesco Currencyshares Japanese Yen Trust (FXY) The Japanese yen is considered a safe-haven currency in times of uncertainty. Investors could tap this via FXY, which appears to be a great way to play a future rise in the yen. It tracks the price of the Japanese yen and charges 40 bps a year in fees. The fund sees a good volume of roughly 340,000 shares per day and has accumulated $856 million in its asset base. FXY has a Zacks ETF Rank #3 with a Medium risk outlook. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report iShares 20+ Year Treasury Bond ETF (TLT): ETF Research Reports SPDR Gold Shares (GLD): ETF Research Reports Invesco CurrencyShares Japanese Yen Trust (FXY): ETF Research Reports Invesco DB US Dollar Index Bullish ETF (UUP): ETF Research Reports This article originally published on Zacks Investment Research ( Zacks Investment Research
See - Sada Elbalad
07-06-2025
- Business
- See - Sada Elbalad
Silver Heats Up — Is It Headed Toward $50?
Waleed Farouk After years of lagging behind gold and remaining relatively stagnant, silver is finally making a notable upward move. But why now? What's fueling this sudden breakout? Peter Krauth, a precious metals expert and author of The Great Silver Bull, believes this is more than just a short-term rally — it's the result of deep, mounting economic forces now surfacing in the market. Inflation Is No Longer 'Transitory' According to Krauth, inflation has become a permanent feature of today's economic reality, no longer just a "transitory phase." He points to the Core PCE index — the Federal Reserve's preferred inflation gauge — which has risen from 2.75% to 3.5% in just a few months, far above the Fed's 2% target. Coupled with a slowdown in GDP growth in the first quarter, Krauth sees the makings of a classic case of stagflation — weak economic growth paired with rising prices. Warning Signs from the Bond Market This outlook is supported by bond market signals. U.S. Treasury yields are climbing, signaling falling bond prices. Krauth highlights the 20-year Treasury bond ETF (TLT), which appears poised to break below previous lows — a sign of declining investor confidence in government debt instruments. Meanwhile, the yield on 30-year Treasuries has surged from just 0.1% during the height of the COVID-19 crisis to nearly 5% today — a historic shift that places major pressure on U.S. debt servicing. Massive Debt and Imminent Maturities Out of the total $36 trillion in U.S. national debt, $9 trillion is set to mature this year alone. According to Krauth, the only viable way to service this is by printing more money — a move that fuels further inflation fears and drives investors toward safe-haven assets like precious metals. Gold Led the Way… Silver Is Catching Up While gold has already priced in much of the inflation risk, Krauth says silver is only just beginning to react. Recent political tensions may also be playing a role — particularly the clash between Donald Trump and Elon Musk, who has criticized Trump's massive spending plans as highly inflationary. Could Silver Hit $50? Krauth forecasts silver could reach around $40 in the second half of this year, with a strong possibility of breaking the long-standing $50 barrier sometime in 2026. If that level is surpassed, he expects silver could surge further, reaching $60–$65, driven by momentum and the lack of historical precedent. He concludes: > 'Once silver breaks above $50, we'll be in completely uncharted territory... and we could see prices we never imagined before.' --- Would you like this version tailored for social media, a newsletter, or broadcast copy as well? read more CBE: Deposits in Local Currency Hit EGP 5.25 Trillion Morocco Plans to Spend $1 Billion to Mitigate Drought Effect Gov't Approves Final Version of State Ownership Policy Document Egypt's Economy Expected to Grow 5% by the end of 2022/23- Minister Qatar Agrees to Supply Germany with LNG for 15 Years Business Oil Prices Descend amid Anticipation of Additional US Strategic Petroleum Reserves Business Suez Canal Records $704 Million, Historically Highest Monthly Revenue Business Egypt's Stock Exchange Earns EGP 4.9 Billion on Tuesday Business Wheat delivery season commences on April 15 News China Launches Largest Ever Aircraft Carrier Sports Former Al Zamalek Player Ibrahim Shika Passes away after Long Battle with Cancer Lifestyle Get to Know 2025 Eid Al Adha Prayer Times in Egypt Sports Neymar Announced for Brazil's Preliminary List for 2026 FIFA World Cup Qualifiers News Prime Minister Moustafa Madbouly Inaugurates Two Indian Companies Arts & Culture New Archaeological Discovery from 26th Dynasty Uncovered in Karnak Temple Business Fear & Greed Index Plummets to Lowest Level Ever Recorded amid Global Trade War Arts & Culture Zahi Hawass: Claims of Columns Beneath the Pyramid of Khafre Are Lies News Flights suspended at Port Sudan Airport after Drone Attacks News Shell Unveils Cost-Cutting, LNG Growth Plan
Yahoo
03-06-2025
- Business
- Yahoo
Soitec and PSMC collaborate on ultra-thin TLT technology for nm-scale 3D stacking
Soitec and PSMC collaborate on ultra-thin TLT technology for nm-scale 3D stacking Bernin (France), June 3, 2025 – Soitec (Euronext – Tech Leaders), a world leader in the design and production of innovative semiconductor materials, today announced a strategic collaboration with Powerchip Semiconductor Manufacturing Corporation (PSMC). Under the collaboration, Soitec will supply PSMC 300mm substrates incorporating a release layer, Transistor Layer Transfer (TLT) ready, to support a new demonstration of advanced 3D chip stacking at the wafer level. This marks the first public announcement of Soitec's TLT technology. The technology is an enabler for next-generation semiconductor designs that allow for more powerful, compact and energy-efficient chips – with potential applications ranging from smartphones, tablets and AI devices to autonomous driving systems. Soitec's Chief Technology Officer and Senior EVP Innovation, Christophe Maleville said: 'At Soitec we are proud to pioneer semiconductor materials that unlock new possibilities in chip design and performance. Our collaboration with PSMC reflects a shared commitment to pushing the boundaries of 3D integration and supporting the global shift toward more efficient and compact computing architectures. Together we are laying the groundwork for the next generation of semiconductor innovation.' PSMC Chief Technology Officer SZ Chang said: 'With our longstanding presence in memory and logic foundry, PSMC consistently drives advancements in 3D stacking. In the two-year collaboration, PSMC has demonstrated an innovative wafer-stack integrated process by leveraging Soitec's advanced substrate technology. The innovation significantly broadens the 3D technology from chip-level stacking - optimizing power performance in computing architecture, to transistor-level stacking – extending Moore's law, with a remarkable reduction in stacking wafer thickness from micrometer to nanometer level. This achievement, by pushing the boundaries of 3D stacking, reaffirms our position at the forefront of the semiconductor industry.' To meet growing industry demand for faster and more energy-efficient chips, Soitec has developed a new substrate stack enabling high-speed transfer of ultra-thin transistor layers onto different types of wafers—a key requirement in heterogeneous integration, where diverse chip components are combined in a single package. The stacking process enables multiple transistor layers to be built vertically to support 3D transistor architectures including vertical field-effect transistors (FETs) with backside power delivery networks (PDNs). This TLT substrate leverages Smart Cut™ technology together with infrared (IR) laser release processing. The proprietary Soitec technology enables the formation of an ultra-thin semiconductor layer, ranging from 5nm to 1µm in thickness, on top of the TLT substrate. Once devices are fabricated on the TLT wafer, the IR laser process facilitates the lift-off of the ultra-thin layer from the substrate to the target wafer, without introducing thermal stress or damaging the devices. The Soitec-PSMC collaboration builds on existing France-Taiwan cooperation initiatives in AI and other semiconductor-related domains. ***** About Soitec Soitec (Euronext - Tech Leaders), a world leader in innovative semiconductor materials, has been developing cutting-edge products delivering both technological performance and energy efficiency for over 30 years. From its global headquarters in France, Soitec is expanding internationally with its unique solutions, and generated sales of 0.9 billion Euros in fiscal year 2024-2025. Soitec occupies a key position in the semiconductor value chain, serving three main strategic markets: Mobile Communications, Automotive and Industrial, and Edge and Cloud AI. The company relies on the talent and diversity of its 2,300 employees, representing 50 different nationalities, working at its sites in Europe, the United States and Asia. Soitec has registered over 4,000 patents. Soitec, SmartSiC™ and Smart Cut™ are registered trademarks of Soitec. For more information: and follow us on LinkedIn and X: @Soitec_Official Media Relations: media@ Investor Relations: investors@ ***** About Powerchip Semiconductor Manufacturing Corporation (PSMC) Powerchip Semiconductor Manufacturing Corporation (PSMC) is the world's seventh-largest pure-play foundry, with four 12-inch and two 8-inch fabs in Taiwan, capable of producing over 2.1 million 12-inch equivalent wafers annually. Since its establishment in 1994, the company transitioned successfully from DRAM manufacturing to advanced foundry services for memory and logic chips. Ranked seventh in global semiconductor ESG evaluations, PSMC demonstrates strong governance and environmental commitment. In May 2024, PSMC's new 12-inch fab in Taiwan's Tongluo Science Park began operations with a planned capacity of 1.2 million wafers annually, using advanced 28nm and wafer stacking technologies. For more information, visit Attachment 20250603_PR Soitec-PSMC TLT CollaborationError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-06-2025
- Business
- Yahoo
BlackRock's ‘Widow Maker' ETF Is Suddenly in High Demand
With a nickname like 'widow maker,' you'd think investors would stay away. The iShares 20+ Year Treasury Bond ETF (TLT), which got its moniker because of its recent poor performance — took in $1.3 billion assets in the past week, according to CFRA Research. Since long-term Treasury bonds are more susceptible to the effects of interest rate changes as they mature, short or intermediate bonds are often more appealing. And for TLT, if investors bought the fund five years ago, they would have lost some 45% of their original assets, according to the Financial Times. But, it looks like long-term products are increasingly on the menu. 'TLT is often used by investors to buy the dip when they think [Fed interest] rates have peaked,' said Aniket Ullal, head of ETF Research & Analytics at CFRA. 'We may be seeing similar behavior here since inflation numbers have been fairly benign recently.' READ ALSO: Nasdaq Wants to Wrap This $11.5B Altcoin in an ETF and Vanguard's 2 New Muni ETFs Have an Advantage Over Mutual Funds The bond market had a small win last week as both 20-year and 30-year Treasury yields began trading just below 5%, the first time since May 20. And while President Donald Trump doesn't have the authority to lower interest rates, he's made his position well known, recently telling Fed Chair Jerome Powell he's making a 'mistake' by not lowering them. Plus, who could forget all that volatility? All this could be contributing to TLT's momentum. 'Investors in long-term Treasury bond ETFs like TLT will win if the US economy weakens significantly and investors believe the Fed will need to cut rates aggressively,' said Todd Rosenbluth, head of research at VettaFi. However, he noted that TLT doesn't have the strongest track record, and taking on significant duration risk has not been rewarding for investors: Over the past five years, the fund has taken in roughly $50 billion in inflows, per VettaFi data. But, its performance is down nearly 50% in that same time. 'Timing this trade can be very difficult,' Ullal told Advisor Upside. This post first appeared on The Daily Upside. To receive exclusive news and analysis of the rapidly evolving ETF landscape, built for advisors and capital allocators, subscribe to our free ETF Upside newsletter. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
30-05-2025
- Business
- Globe and Mail
Theralase(R) 1Q2025 Financial Statements
Toronto, Ontario--(Newsfile Corp. - May 30, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (" Theralase®" or the " Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses has released the Company's unaudited interim consolidated 1Q2025 financial statements (" Financial Statements"). Theralase® will be hosting a conference call on Monday June 9 th, 2025 at 11:00 am ET, which will include a presentation of the financial and operational results for the fiscal quarter ending March 31 st, 2025. Questions are welcome; however, to ensure we have time to review and properly address them during the call, please send them in advance to mperraton@ An archived version will be available on the website following the conference call. 1 Other represents foreign exchange, interest accretion on lease liabilities and / or interest income To view an enhanced version of this graphic, please visit: Financial Highlights For the three-month period ended March 31, 2025: Total revenue was $91,190, compared to $175,554 in Q1 2024, a 48% year-over-year decrease. Cost of sales was $77,896 (85% of revenue), resulting in a gross margin of $13,294 (15% of revenue), down from $62,114 (35% of revenue) in Q1 2024. Selling expenses were $68,143, essentially flat compared to $67,552 in the prior year. Administrative expenses rose to $555,074 from $511,495, a 9% increase driven primarily by professional fees and stock-based compensation. Research and development expenses were $877,670, up from $756,380, reflecting increased activity to support Study II progress. Net loss for the period was $1,471,250, compared to $1,266,711 in Q1 2024. This includes $220,538 in non-cash charges such as amortization and stock-based compensation. Operational Highlights Private Placements On March 10, 2025, the Company closed a non-brokered private placement of 1,034,002 units at $0.30 per unit for gross proceeds of $310,201. Each unit consisted of one common share and one non-transferable common share purchase warrant exercisable at $0.45 for five years. Net proceeds were $304,633, after transaction costs. On April 22, 2025, the Company completed another non-brokered private placement, issuing 1,995,829 units at $0.21 per unit for gross proceeds of $419,124. Each unit included one common share and one non-transferable common share purchase warrant exercisable at $0.32 for five years. The Company has raised approximately $CAN 6.3 million over the last 2 years through non-brokered private placements in support of its research and development programs. It is currently investigating the use of a full-service investment bank in the United States to advise on potential financings and US listing opportunities. Information on any future financings will be released once available in accordance with applicable securities laws. Herpes Simplex Virus ("HSV") Treatment Program Theralase® continues preclinical development of its HSV treatment using non-light activated and light-activated small molecules. The Company is actively working on in-vitro, and in the near future, in-vivo HSV preclinical models to finalize a formulation for optimal dermal penetration to increase patient safety and efficacy. Good Laboratory Practice (" GLP") toxicology studies will commence once a formulation has been finalized. Additional details will be announced as strategic objectives are achieved. Phase II Bladder Cancer Study Update ("Study II") 82 patients have been treated with the Study Procedure, representing approximately 91% of the total targeted enrollment of 90 evaluable patients. 69 patients have completed their 90-day assessment and are considered evaluable for interim efficacy analysis. 13 additional patients are pending their 90-day assessment and will be included in future efficacy updates once evaluations are complete. Interim Clinical Results For the primary endpoint of Study II (Complete Response (" CR") at any point in time) 62% of patients provided the Study Procedure (Study Drug activated by the Study Device) demonstrated a CR. Including patients, who demonstrated an Indeterminate Response (" IR") (negative cystoscopy and positive or suspicious urine cytology), the Total Response ("TR") increases to 70%. This represents that approximately 2 out of 3 BCG-Unresponsive NMIBC CIS patients treated with Theralase®'s unique Study Procedure are demonstrating complete destruction of their bladder cancer. For the secondary endpoint of Study II (duration of CR) 42% of treated patients who achieved a CR, maintained their CR response for at least 12 months (450 days from date of Study Procedure). For the tertiary endpoint of Study II (safety of Study Procedure) 100% (69/69) experienced no Serious Adverse Events (" SAEs") directly related to the Study Drug or Study Device. Outside of the defined endpoints of Study II, Theralase® has demonstrated a duration of CR at extended time points of 23% at 2 years, 21% at 3 years and 2% at 7 years. Note: Not all patients have been assessed at these extended time points. As more clinical data is collected, the duration of CR at 2, 3 and 7 years may increase. Theralase® is on track to complete enrollment in Study II by the summer of 2025. This will allow the Company to report on 75 patients who have completed Study II in December 2025 and to report on all 90 patients by September 2026. Upon follow-up of all patients, the Company plans to submit a New Drug Application ("NDA") to Health Canada and the FDA in 4Q2026, with a decision expected by the respective regulatory authorities on a marketing approval in 2027. As Theralase® completes enrollment in Study II, it is actively searching for commercialization partners for international marketing and sales of Ruvidar®. To this end, Theralase® is in various stages of initial and advanced discussions with international pharmaceutical companies for various geographical territories concerning: Licensing of the light-activated Ruvidar® for BCG-Unresponsive NMIBC CIS Collaborative research focused on investigating light-activated Ruvidar® in the treatment of NMIBC Collaborative research focused on combining Ruvidar® with other FDA approved drugs In recent discussions with the FDA, the Company has decided that since Study II is 91% complete, the best course of action is not to pursue Break Through Designation, but to complete Study II and submit the clinical data to the FDA in a formal NDA. At the end of the meeting, the FDA made a comment that they were impressed that the interim clinical data obtained to date was able to be achieved with only one clinical treatment, in the majority of cases. Ruvidar® has demonstrated 10 years of shelf life, strongly supporting the stability of the molecule and the ability of clinics to store the small molecule for extended periods of time. Additional Oncology Targets Theralase® has combined Ruvidar® with transferrin (human glycoprotein) to form Rutherrin®. Rutherrin® is a strong candidate for the systemic treatment of recurrent, deep seated and/or progressive cancers. Due to the limitations of using laser light to activate Rutherrin® in deep oncological targets, Theralase® plans to activate Rutherrin® with radiation therapy to increase the "tumour's damage zone" and the effectiveness of Theralase®'s small molecule beyond the reach of light in the body. Rutherrin®, if clinically proven, will be able to "hunt" and "localize" into cancer cells and when activated by radiation "destroy" them; wherever, they may reside in the body. The Company expects to complete Good Laboratory Practice toxicology analysis in 4Q2025 to allow commencement of a Phase 0/I/II adaptive clinical study in 1Q2026 for the following indications: 1) Glio Blastoma Multiforme (" GBM") Brain Cancer Treatment 2) Non-Small Cell Lung Cancer (" NSCLC") Treatment 3) Pancreatic Cancer 4) Colorectal Cancer 5) Muscle Invasive Bladder Cancer (" MIBC") Treatment 6) Herpes Simplex Virus (" HSV-1") Topical Treatment for Cold Sore Lesions For additional information, please refer to the Company's Management's Discussion and Analysis ("MD&A") available at About Ruvidar®: Ruvidar®(TLD-1433) is a small molecule, able to be activated by light, radiation, sound and/or other drugs, intended for the safe and effective destruction of various cancers, bacteria and viruses. About Theralase® Technologies Inc.: Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. Additional information is available at and Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements: This news release contains Forward-Looking Statements (" FLS") within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words " may, " should", " will", " anticipates", " believes", " plans", " expects", " estimate", " potential for" and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals. These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and drug formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict. Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS. Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS. All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS. For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies.
